Fig. 6

Long-term treatment of A375 cells with single inhibitors or synergistic drug combinations. a Parental A375 cells expressing iRFP were treated for up to 76 days (11 weeks) with the BRAF inhibitor Dabrafenib alone or in combination with selected kinase inhibitors. b Parental and BRAFi-resistant A375 cells (-XP: Vemurafenib-resistant; -GP: Dabrafenib-resistant) expressing iRFP were long-term treated with a Wee1i (MK-1775) alone or in combination with a Chki (AZD7762) at the indicated concentrations. Cell growth was monitored over time by quantifying fluorescence on a LICOR Odyssey Imaging system (at least 3 wells per treatment). Red circles indicate wells with saturation, where no fluorescence quantification in the linear range was possible. Red arrows mark the timepoint (after day 76) when drugs were removed from the medium. The combined treatment was set to 1. Dabra: Dabrafenib